Olukorode John O, Orimoloye Dolapo A, Nwachukwu Nwachukwu O, Onwuzo Chidera N, Oloyede Praise O, Fayemi Temiloluwa, Odunaike Oluwatobi S, Ayobami-Ojo Petra S, Divine Nwachi, Alo Demilade J, Alex Chukwurah U
Internal Medicine, Babcock University Teaching Hospital, Ilishan-Remo, NGA.
Internal Medicine, College of Medicine, University of Lagos, Lagos, NGA.
Cureus. 2024 Oct 21;16(10):e72080. doi: 10.7759/cureus.72080. eCollection 2024 Oct.
Glucagon-like peptide-1 (GLP-1) agonists have emerged as a groundbreaking class of medications for managing type 2 diabetes and associated metabolic disorders. These agents not only improve glycemic control by increasing insulin secretion and reducing glucagon levels but also promote significant weight loss, enhance cardiovascular and renal health, and offer potential neuroprotective benefits. Their multifaceted mechanisms include appetite suppression, increased energy expenditure, and direct neuroprotective effects. GLP-1 agonists have shown recent benefits in Obstructive Sleep Apnea, and the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as reducing the risk of stroke. This review highlights the therapeutic potential of GLP-1 agonists in diabetes management and beyond, advocating for continued research to optimize their clinical use and explore new therapeutic avenues.
胰高血糖素样肽-1（GLP-1）激动剂已成为治疗2型糖尿病及相关代谢紊乱的一类开创性药物。这些药物不仅通过增加胰岛素分泌和降低胰高血糖素水平来改善血糖控制，还能显著促进体重减轻，增强心血管和肾脏健康，并具有潜在的神经保护作用。它们的多方面作用机制包括抑制食欲、增加能量消耗以及直接的神经保护作用。GLP-1激动剂最近在阻塞性睡眠呼吸暂停、阿尔茨海默病和帕金森病等神经退行性疾病的治疗中显示出益处，还能降低中风风险。本综述强调了GLP-1激动剂在糖尿病管理及其他方面的治疗潜力，主张持续开展研究以优化其临床应用并探索新的治疗途径。
